101 – 150 of 247
- show: 50
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2008
-
Mark
Biomarkers in the prediction of radiographic progression in early rheumatoid arthritis: comment on the article by Young-Min et al - Reply
(
- Contribution to journal › Letter
-
Mark
The Swedish biologics register (ARTIS): observations of adverse events when using biologics in clinical practice
(
- Contribution to journal › Published meeting abstract
-
Mark
COMP a candidate molecule in the pathogenesis of systemic sclerosis with a potential as a disease marker
(
- Contribution to journal › Article
-
Mark
Efficacy and tolerability of anti-TNF therapy in psoriatic arthritis patients: Results from the South Swedish Arthritis Treatment Group Register.
(
- Contribution to journal › Article
-
Mark
Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register.
(
- Contribution to journal › Article
-
Mark
Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register.
(
- Contribution to journal › Article
-
Mark
Orthopaedic surgery in patients with rheumatoid arthritis over 20 years: prevalence and predictive factors of large joint replacement
(
- Contribution to journal › Article
- 2007
-
Mark
Neurosarcoidosis in a patient with rheumatoid arthritis during treatment with infliximab
(
- Contribution to journal › Letter
-
Mark
Development of draft validation criteria for a soluble biomarker to be regarded as a valid biomarker reflecting structural damage endpoints in rheumatoid arthritis and spondyloarthritis clinical trials
(
- Contribution to journal › Article
-
Mark
Biomarkers predict radiographic progression in early rheumatoid arthritis and perform well compared with traditional markers
(
- Contribution to journal › Article
-
Mark
The impact of IL-1Ra and MBL gene polymorphisms on joint damage after 5 and 10 years in patients with early rheumatoid arthritis
(
- Contribution to journal › Letter
-
Mark
The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review.
(
- Contribution to journal › Article
-
Mark
Research in hand osteoarthritis: time for reappraisal and demand for new strategies. An opinion paper
(
- Contribution to journal › Scientific review
-
Mark
Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists
(
- Contribution to journal › Article
-
Mark
Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients.
(
- Contribution to journal › Article
-
Mark
Monitoring patients treated with anti-TNF- biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies
(
- Contribution to journal › Article
-
Mark
Behandling af reumatoid artrit med anti-tumornekrosefaktor-alpha-antistof. Individuel monitorering af biotilgaengelighed og immunogenicitet-- sekundaerpublikation
(
- Contribution to journal › Article
-
Mark
Treatment with TNF-blockers and mortality risk in patients with rheumatoid arthritis.
(
- Contribution to journal › Article
- 2006
-
Mark
Classification of osteoarthritis biomarkers: a proposed approach
(
- Contribution to journal › Scientific review
-
Mark
The heritable determinants of cartilage oligomeric matrix protein
(
- Contribution to journal › Article
-
Mark
Predictors of infusion reactions during infliximab treatment in patients with arthritis.
(
- Contribution to journal › Article
-
Mark
Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden
(
- Contribution to journal › Article
-
Mark
The LUNDEX, a new index of drug efficacy in clinical practice: results of a five-year observational study of treatment with infliximab and etanercept among rheumatoid arthritis patients in southern Sweden.
(
- Contribution to journal › Article
-
Mark
Diurnal variation in serum levels of cartilage oligomeric matrix protein in patients with knee osteoarthritis or rheumatoid arthritis
(
- Contribution to journal › Article
-
Mark
Anti-inflammatory effects of contralateral administration of the kappa-opioid agonist U-50,488H in rats with unilaterally induced adjuvant arthritis
(
- Contribution to journal › Article
-
Mark
Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab
(
- Contribution to journal › Article
-
Mark
Non-collagenous Proteins; Glycoproteins and related proteins
2006) p.71-84(
- Chapter in Book/Report/Conference proceeding › Book chapter
-
Mark
Serum levels of Cartilage Oligomeric Matrix Protein (COMP) increase temporarily after physical exercise in patients with knee osteoarthritis
(
- Contribution to journal › Article
-
Mark
Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis.
(
- Contribution to journal › Article
-
Mark
Biomarkers for cartilage and bone in rheumatoid arthritis
2006) p.301-301(
- Chapter in Book/Report/Conference proceeding › Book chapter
-
Mark
Allvarlig lungsjukdom vid RA och TNF-blockering--finns det ett samband?
(
- Contribution to journal › Article
-
Mark
Noncollagenous Proteins: Glycoproteins and Related Proteins
2006) p.71-84(
- Chapter in Book/Report/Conference proceeding › Book chapter
-
Mark
Glukosamin hjälper inte mot smärta vid knäartros
(
- Contribution to journal › Letter
- 2005
-
Mark
Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis
(
- Contribution to journal › Article
-
Mark
Prediction of mortality in rheumatoid arthritis based on disease activity markers.
(
- Contribution to journal › Article
-
Mark
No increase of severe infections in RA patients treated with TNF-blockers
2005) Annual European Congress of Rheumatology, 2005 In Annals of the Rheumatic Diseases 64(Suppl. 3). p.461-462(
- Contribution to journal › Published meeting abstract
-
Mark
Population based studies of biological antirheumatic drug use in southern Sweden: comparison with pharmaceutical sales
(
- Contribution to journal › Letter
-
Mark
Results from a nationwide postmarketing cohort study of patients in Sweden treated with etanercept
(
- Contribution to journal › Article
-
Mark
Changes of cartilage and bone markers after intraarticular glucocorticoid treatment with and without postinjection rest in patients with rheumatoid arthritis
(
- Contribution to journal › Article
-
Mark
Prognostic laboratory markers of joint damage in rheumatoid arthritis.
(
- Contribution to journal › Article
-
Mark
Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas
(
- Contribution to journal › Article
-
Mark
Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists
(
- Contribution to journal › Article
-
Mark
Matrix Glycoproteins and Proteoglycans in Cartilage
(
- Chapter in Book/Report/Conference proceeding › Book chapter
-
Mark
Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists
(
- Contribution to journal › Article
-
Mark
CNI-1493, an inhibitor of proinflammatory cytokines, retards cartilage destruction in rats with collagen induced arthritis
(
- Contribution to journal › Article
-
Mark
Response criteria for rheumatoid arthritis in clinical practice - how useful are they?
(
- Contribution to journal › Article
-
Mark
Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden
(
- Contribution to journal › Article
- 2004
-
Mark
Hormone replacement therapy, calcium and vitamin D-3 versus calcium and vitamin D-3 alone decreases markers of cartilage and bone metabolism in rheumatoid arthritis: a randomized controlled trial [ISRCTN46523456]
(
- Contribution to journal › Article
-
Mark
Fibronectin fragments cause release and degradation of collagen-binding molecules from equine explant cultures.
(
- Contribution to journal › Article
-
Mark
Results of anakinra treatment in rheumatoid arthritis patients previously treated with tumor necrosis factor alpha blockade: comment on the article by Buch et al
(
- Contribution to journal › Letter